← Human Trials & Peer-Reviewed Studies
A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration
Plain-language guide to PMID 18048059 (2008): pilot controlled clinical trial of Cerebrolysin.
Key Facts
- PMID
- 18048059
- Journal
- Journal of the neurological sciences
- Year
- 2008
- Study type
- Controlled Clinical Trial
- Authors
- Muresanu DF et al. (8 authors)
- DOI
- 10.1016/j.jns.2007.10.016
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Cerebrolysin, published as a controlled clinical trial.
The effects of the neurotrophic compound Cerebrolysin (Cere) on cognitive performance, evaluated with the ADAS-cog, and on qEEG activity were investigated in forty one patients with mild to moderate severe probable vascular dementia (VaD) according to NINDS-AIREN criteria, included in a placebo-controlled pilot study.
Mean score of change from baseline in the ADAS-cog and percent change from baseline in slow to fast EEG power ratio (PR) scores were the two primary endpoints.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.
How the Study Was Run
The design is described as placebo-controlled and pilot.
The comparison arm used a placebo, so changes seen with Cerebrolysin could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Cerebrolysin study would be practical.
What Was Measured
The effects of the neurotrophic compound Cerebrolysin (Cere) on cognitive performance, evaluated with the ADAS-cog, and on qEEG activity were investigated in forty one patients with mild to moderate severe probable vascular dementia (VaD) according to NINDS-AIREN criteria, included in a placebo-controlled pilot study.
Mean score of change from baseline in the ADAS-cog and percent change from baseline in slow to fast EEG power ratio (PR) scores were the two primary endpoints.
PubMed files the paper under topics including Alpha Rhythm, Amino Acids, Brain, Cognition, Cognition Disorders, Dementia, Vascular and Electroencephalography.
What This Means in Plain Language
The paper is a placebo-controlled and pilot study of Cerebrolysin.
The publication is from 2008 (Journal of the neurological sciences), a journal based in Netherlands.
More context: the Cerebrolysin compound page, all human trials.
Our Notes on the Compound
Cerebrolysin: A mixed neurotrophic preparation (NGF-, BDNF-, GDNF- and CNTF-like activity).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.